A Phase 2 interventional study of Paxlovid 5 days and Paxlovid 10 days in COVID-19 and Immunodeficiency, sponsored by Calmy Alexandra. Recruiting at 4 sites in Switzerland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.
Sponsored by Calmy Alexandra · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.
Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 17th largest by planned enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2023, is one of 8 in phase 2, and was the 97th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:
Flurin Cathomas · Sites in Switzerland
Ages 18–65
Universitaire Ziekenhuizen KU Leuven · Sites in Switzerland, Belgium, Germany
Ages 18–70
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–120
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18+
UMC Utrecht · Sites in Switzerland, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 21 · Phase 4 2
First in 2016; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 100 across the 49 interventional studies, 425 across the 47 observational. Of the 70 that completed or were terminated, 11 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 97 have an industry lead sponsor. The 10 most frequent:
Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Calmy Alexandra has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies in COVID-19 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482138Universitaire Ziekenhuizen KU LeuvenDysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation | 2026-12-31 |
| NCT06716996Flurin CathomasRTMS for the Treatment of Post-COVID Associated Affective Symptoms | 2027-10-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 97 studies in COVID-19 with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).
This is a randomized, controlled, factorial, superiority trial to evaluate the viral efficacy of direct antiviral agent nirmatrelvir/r + direct antiviral agent remdesivir versus nirmatrelvir/r alone and of 5 days versus 10 days of nirmatrelvir/r in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19. The primary objective is to assess whether (i) a combination antiviral therapy of two antiviral agents (nirmatrelvir/r + remdesivir and/or (ii) an increase in nirmatrelvir/ r duration from 5 to 10 days improves viral efficacy by decreasing the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2) positivity rate by real time polymerase chain reaction (RT-PCR) (cycle threshold CT\<32) in nasopharyngeal swabs at day 10 (D10). Patients will be eligible if they are immunocompromised, have confirmed asymptomatic SARS-CoV-2 infection or mild to moderate COVID-19, regardless of symptoms onset, provided that they have no contra-indication to any of the study drugs. A total of 256 patients will be recruited in Switzerland and in France, Italy and Norway (through the parallel protocol ANRS0176s OPTICOV).
Participants not eligible for randomisation or who refuse to participate to the trial for any reason will be proposed to be included in an exploratory non comparative cohort (maximum 97 participants, active only in Switzerland).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the Federal Office of Public Health (FOPH) list (criteria 5: diseases/treatments leading to immune suppression) or other immunosuppression criteria such as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nirmatrelvir/r 300mg/100 mg bis in die (twice a day, bid) will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Paxlovid® for 5 days is the standard of care.
Drug: Paxlovid 5 days
Intervention Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
Drug: Paxlovid 10 days
Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Drug: Paxlovid 5 days
Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally. Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Drug: Paxlovid 10 days
Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
Virological
Percentage of patients with SARS-CoV-2 viral load \<32 cycle threshold (CT) by real-time RT-PCR in nasopharyngeal swabs at D10 after treatment initiation.
Time frame: Day 10
Virological
Percentage of patients with SARS-CoV-2 viral load \<32 CT by real-time RT-PCR in nasopharyngeal swabs at D5, D14 and D21 after treatment initiation
Time frame: Day 5, Day 14, Day 21
Virological
Percentage of patients with detectable SARS-CoV-2 viremia at D5, D10 and D14
Time frame: Day 5, Day 10, Day 14
Virological
Decrease of SARS-CoV-2 viral load measured by copies/ml by nasopharyngeal swab at D5, D10, D14, D21 and at D5, D10 and D14 in blood samples comparatively to screening
Time frame: Day 5, Day 10, Day 14, Day 21
Virological
Number of de novo mutations after sequencing on nasopharyngeal swabs at D5, D10, D14 and D21 comparatively to screening
Time frame: Day 5, Day 10, Day 14, Day 21
Virological
To assess the phenotypic resistance (Half maximal inhibitory concentration (IC50) increase) against treatment for viral strains cultured from nasopharyngeal swabs at D5, D10, D14 and D21 comparatively to screening
Time frame: Day 5, Day 10, Day 14, Day 21
Virological
Time to first negative SARS-CoV-2 RT-PCR (CT\<32) until D90
Time frame: Day 90
Virological
Absence of ability to cultivate virus from viral cultures from nasopharyngeal swabs at D5, D10, D14 and D21
Time frame: Day 5, Day 10, Day 14, Day 21
Clinical
Percentage of patients with sustained resolution or abatement of symptoms defined as a inFLUenza Patient-Reported Outcome Plus (FLU-PRO-Plus) score ≤1 at D5, D10, D14, D21 and D28
Time frame: Day 5, Day 10, Day14, Day 21, Day 28
Clinical
All-cause hospitalization and/or death at D28
Time frame: Day 28
Clinical
Hospitalization at D28
Time frame: Day 28
Clinical
Death at D28
Time frame: Day 28
Clinical
inFLUenza Patient-Reported Outcome Plus (FLU-PRO-Plus) scale at D5, D10, D14, D21, D28 and D90. Scores range from 0 (symptom free) to 4 (very severe symptoms).
Time frame: Day 5, Day 10, Day 14, Day 21, Day 28, Day 90
Clinical
Rate of Post-COVID19 condition at D90 according to the World Health Organisation (WHO) October 2021 definition
Time frame: Day 90
Clinical
Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to D90
Time frame: Day 90
Clinical
Adherence to nirmatrelvir/r with patient-reported adherence and nirmatrelvir/r residual plasma dosage at D5 and D10, if applicable
Time frame: Day 5, Day 10
Clinical
Number of drud-drug interactions who led to dosage adjustment of other patient's drugs
Time frame: Day 10
Clinical
Immunosuppressors residual concentrations, if applicable
Time frame: Day 10
Clinical
Percentage of patients with specific retreatment (by antiviral, anti-inflammatory drug or convalescent plasma) through D90
Time frame: Day 90
Clinical
Number of drug-drug interactions (DDIs) which led to dosage adjustment of other patient's drugs
Time frame: Day 10
Treatment discontinuation outcome because of AE or SAE
Percentage of participants with an adverse event (AE) or serious adverse event (SAE) or AE leading to treatment discontinuation up to D90
Time frame: Day 90
Plan to share: No — Individual Participant Data are described in the study protocol
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Apr 2026, 35 months after the start.
Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 35 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Calmy Alexandra